CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…